Spierings, Julia, Sloeserwij, Annemiek, Vianen, Marieke E, de Boer, Joke H, Sigurdsson, Vigfus, van de Wijgert, Janneke HHM ORCID: 0000-0003-2728-4560 and van Laar, Jacob M
(2020)
Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study.
CLINICAL IMMUNOLOGY, 214.
108392-.
Text
2020 QoL in IMID Patients Spierings ClinImm.pdf - Published version Download (709kB) | Preview |
Abstract
Immune mediated inflammatory diseases (IMIDs) have similarities in pathophysiology and treatment. Not much is known, however, about health-related quality of life (HR-QoL) in IMIDs. We assessed and compared HR-QoL, using the validated EuroQoL 5-dimensions 5-levels questionnaire, in an observational cohort comprising 530 patients (67.5% female, mean age 49 years (95% CI 35.9-50.9), mean disease duration 31.0 months (95% CI 27.2-34.8)), with the following IMIDs: connective tissue diseases (32.6%), uveitis (20.8%), inflammatory arthritis (17.7%), psoriasis (15.5%), vasculitis (6.2%), primary antiphospholipid syndrome (4.2%), and autoinflammatory diseases (2.8%). Patients used either no anti-inflammatory therapy (31.5%), monotherapy (28.7%), or a combination of anti-inflammatory drugs (39.8%). The mean HR-QoL utility score was 0.75 (95% CI 0.72-0.78). Multinominal logistic regression analysis showed a statistically significant association between a very low HR-QoL (utility score (<0.70)) and female sex, rheumatological IMID or psoriasis, smoking or having smoked in the past, and current biological disease modifying anti-rheumatic drugs use.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Immune mediated inflammatory diseases, Health-related quality of life, Biological disease modifying anti-rheumatic drugs |
Depositing User: | Symplectic Admin |
Date Deposited: | 14 Apr 2020 10:33 |
Last Modified: | 18 Jan 2023 23:55 |
DOI: | 10.1016/j.clim.2020.108392 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3082683 |